Get started
Author

Sam Suzuki

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
2008 · Axel Grothey, Eric E. Hedrick, et al. · Journal of Clinical Oncology · 171
PDF
Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19
2023 · Amy L. Lightner, Vikram Sengupta, et al. · CHEST Journal · 157
PDF
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
2019 · Amod Sarnaik, Nikhil I. Khushalani, et al. · Journal of Clinical Oncology · 30
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia
2018 · Susan M. O’Brien, Samantha Jaglowski, et al. · JAMA Oncology · 22
PDF
Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.
2017 · Amod Sarnaik, Harriet M. Kluger, et al. · Journal of Clinical Oncology · 9
Abstract LB-069: Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma
2019 · Viktoria Gontcharova, Sam Suzuki, et al. · Cancer Research · 3
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
2019 · Amod Sarnaik, Sajeve Samuel Thomas, et al. · Journal of Clinical Oncology · 3
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
2018 · Sylvia Mina Lee, Missak Haigentz, et al. · Journal of Clinical Oncology · 3
Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL
2015 · Susan O'Brien, Samantha Jaglowski, et al. · Blood · 3
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
2018 · Amod Sarnaik, Brendan D. Curti, et al. · Journal of Clinical Oncology · 2
Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma
2018 · Amod Sarnaik, Brendan Curti, et al. · Cancer Research · 1
Abstract CT170: A phase II, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2018 · Rom Leidner, Ammar Sukari, et al. · Cancer Research · 1
Abstract LB-069: Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma
2019 · Viktoria Gontcharova, Sam Suzuki, et al. · Immunology
Abstract CT173: A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
2018 · Sylvia Lee, Viktoriya Villaflor, et al. · Cancer Research
Abstract CT172: A phase 2 multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent metastatic or persistent cervical carcinoma
2018 · Amir Jazaeri, Robert Edwards, et al. · Cancer Research
Works count: 15
Citation count: 405
H-index: 5
I10-index: 4
Year
Topic
Type